How to Verify That Your Imported Cancer Medicine Is Genuine — A Safety Guide for Hospital Pharmacists in India 2026
In May 2026, Delhi Police busted a counterfeit medicine racket worth nearly Rs 10 crore — four people arrested for manufacturing and supplying fake life-saving drugs for cancer and liver disease. Fake medicines, packaging equipment, forged labels — all recovered from an operation supplying hospitals across multiple states. Weeks earlier in April 2026, a detailed […]
Palbociclib, Ribociclib and Abemaciclib in India 2026 — Which CDK4/6 Inhibitor Is Right for Your Patient?
Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by a class of medicines called […]
Lutetium-177 PSMA Therapy for Prostate Cancer in India — Who Qualifies, How It Works, and Where to Access It in 2026
For most of the past two decades, Indian men diagnosed with advanced prostate cancer had a fairly narrow set of treatment options — hormone therapy, chemotherapy if the cancer progressed, and more recently oral targeted medicines like Enzalutamide (Glenza) and Abiraterone (Abirapro). These are genuinely effective medicines, but they work for a limited time in […]
Enhertu and the ADC Revolution — Why Antibody-Drug Conjugates Are the Most Important Development in Cancer Treatment in 2026
In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication and was being described by […]